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Abstract
The stability of ceftazidime in 5% dextrose injection and 0.9% sodium chloride injection when stored in a different
disposable infusion device was determined. Solutions of ceftazidime 40 mg/ml were used to fill the drug administra-
tion devices. Stability was determined for both 5% dextrose injection and 0.9% sodium chloride injection solutions at
37 °C in four disposable infusion devices. Ceftazidime and its mean degradation product, pyridine, were simulta-
neously assayed in triplicate by a stability-indicating high-performance liquid chromatographic (HPLC) method. This
method was simple, sensitive (limit of quantitation (LOQ), 2 ng injected for both compounds), rapid (run time was
7 min) and precise (mean recovery was 100.5!2.9 and 103.6!1.9% for pyridine and ceftazidime, respectively). The
ceftazidime stability in the 5% dextrose solution was lower than in the 0.9% sodium chloride solution. When stored
at 37 °C in a disposable infusion device, the stability of the ceftazidime is included in large hourly range, depending
strongly on the manufacturer. The stability of ceftazidime exceed 19 h in none studied cases. The pyridine formed in
24 h was in the range of 100–400 mg depending on devices and infusions. © 2002 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Ceftazidime is a third-generation cephalosporin
that is widely used for the treatment of serious
infections caused by gram-negative bacteria in-
cluding Pseudomonas aeruginosa. It is more resis-
tant than second-generation cephalosporin to
most !-lactamases produced by various species of
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bacteria [1]. !-Lactam antibiotics most effectively
kill bacteria when their concentration remains
above the minimum inhibitory concentration
(MIC) of the infecting organism throughout the
dosing interval; thus, intermittent dosing may not
always provide optimal therapy [2]. The rising
incidence of gram-negative infections, especially
for patients with cystic-fibrosis, and the availabil-
ity of improved intravenous drug delivery systems
have led to the investigation of continuous-infu-
sion !-lactam therapy [3,4]. Administration of
ceftazidime at home by continuous I.V. infusion
was safe, effective and cost-effective [3]. There-
fore, to obtain maximum benefit from this
method of drug delivery, it is necessary to know
the behaviour of drugs under therapeutic drug
concentration, in different available infusion
devices [5]. But, like all cephalosporins, aqueous
solutions of ceftazidime are subject to hydrolysis
reaction [6]. Indeed, influence of pH, temperature,
buffers and concentration on the kinetics of cef-
tazidime degradation in aqueous solutions was
studied [7,8]. The kinetic analysis of ceftazidime
degradation showed first-order hydrolysis [9].
Other studies have examined its stability under
several storage conditions: in plastic syringes and/
or glass vials at different temperatures [10,11], in
normal saline and dextrose in minibags [12], in
drug reservoirs in an insulated pouch enclosed
between two frozen gel packs [13], in a elas-
tomeric infusion device [14]—Singleday Infusor
Baxter—and in PVC infusion bags [15].
The products of degradation are multiple [16],
but one more than the others draw attention, i.e.
pyridine. Indeed, the underestimated toxicity of
pyridine by intravenous way and FDA or USP
texts hint at a maximum tolerated concentration
of pyridine in the medicine [17,18]. Since, several
studies followed the appearance of pyridine dur-
ing the degradation of Fortum in aqueous solu-
tions, in infusion device with two different mobile
phases [19], simultaneously in an eye drop formu-
lation [20,21] by HPLC, in aqueous solution by
capillary electrophoresis [16] and in OutBound®
ambulatory infusion device [22]; this last one esti-
mates the stability of the ceftazidime by measur-
ing the pyridine according to time.
In spite of the important number of articles
telling the stability of the ceftazidime, any of them
do not report such a study on these types of
infusion devices, especially by referring on the
dosage of the pyridine. So, the purpose of this
study was to evaluate the stability of ceftazidime
in 5% dextrose injection or 0.9% sodium chloride
injection, based on the measure of pyridine con-
centration as described in previous study [22],
when stored at 37 °C in four disposable infusion
devices (Infusor®, EasyPump®, UltraFlow®,
OutBound®).
2. Materials and methods
2.1. Materials
Ceftazidime in FortumSet, containing cef-
tazidime pentahydrate (1 or 2 g) with sodium
carbonate, was obtained from Glaxo-Wellcome
(Glaxo-Wellcome, batches V9D04 and V9M03).
The drug was assayed in different disposable infu-
sion devices to simulate ambulatory treatment,
the types of containers used were Infusor® LV 10
(Baxter Laboratories, batches 99D012, 99EO43
and 99DO73), a 240 ml poly-isoprene latex free
device, Easypump® LT 125 (Braun, lot 992091), a
120 ml synthetic elastomer latex free bag, Ultra-
Flow® (Fresenius-Kabi, lots 7284, 7359 and
7498), a 110 ml poly-vinyl chloride (PVC) bag,
and Outbound® (Zambon, lots D990609B,
D990121B and D990316B), 100 ml polyethylene
device. The drug stability was tested in each of
these four systems with 0.9% sodium chloride
injection (Baxter, batches 00A10G50, 00A28G50,
00A31G53, 00C09C2G51 and Aguettant, batch
29201A02) and 5% dextrose injection (Baxter,
batches 00A27S51 and 00B23G50).
Ceftazidime pentahydrate (lot AWS 27E) 84.6%
pure powder was donned by Glaxo-Wellcome
(Evreux, France) and pyridine, 99+% (lot 24263-
039) was obtained from Sigma-Aldrich (St
Quentin-Fallavier, France). All other chemicals
and reagents were of analytical grade or high-per-
formance liquid chromatography (HPLC) grade.
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2.2. Principles of different ambulatory infusion
de!ices
These infusion ambulatory systems work ac-
cording to three different principles. Infusor and
Easypump have an inflatable ‘balloon’ reservoir
surrounded by a protective shell; the pressure
created by the inflated balloon forces the medica-
tion through the tubing. In UltraFlow system, the
pressure is exerted on the infusion bag by a
reusable, spring-loaded, two-part cylindrical hous-
ing with spring. Outbound® system works by
exerting pressure on an internal syringe plunger
equipped with vacuum chamber.
2.3. Preparation of admixtures
Solutions of ceftazidime injection were pre-
pared under sterile conditions at a concentration
of 40 mg/ml. That concentration reflects the rec-
ommended dosage of ceftazidime in commercial
sources for stability and compatibility studies.
More, working in concentration, and not in in-
fused quantity like in cystic fibrosis therapy [3],
simplified analytical handling and data analysis.
The stability of ceftazidime was determined at
37 °C in four brands of disposable infusion
devices. A pooled solution of ceftazidime was
prepared by dissolving Fortum® in the infusion
fluids. The manufacturers’ directions were used to
fill drug administration devices with the following
volumes, Infusor LV 10, 240 ml; EasyPump, 120
ml; UltraFlow, 82.5 ml with 0.9% sodium chloride
solution and 70 ml with 5% dextrose solution;
OutBound, 100 ml.
Three of each device, each being a different lot,
excepted for Braun system, were used to test
concentration– time evolutions of pyridine and cef-
tazidime. Devices were stored in the dark in a
steamer at 37 °C. Every 2 days, one type of device
filled with one type of injection solution was
studied. Every hour, samples were taken in a
collecting glass tube placed at the end of device
capillary outlet. This volume was diluted 1:160 with
mobile phase to about 250 "g/ml of ceftazidime.
The simultaneous measure of ceftazidime and pyr-
idine was made alternately in each of the three
shares. Triplicate injections were done onto HPLC.
2.4. Analysis by high-performance liquid
chromatography
The HPLC assay used was the same method as
Favetta et al. [22]. The instrumentation included a
Kromasil C18 reversed phase column (Interchim,
Montluçon, France), an isocratic pump model
LC-10AD (Shimadzu, Touzart et Matignon,
France), an ultraviolet detector model SPD-
10Avp (Shimadzu) set at 257 nm, a Rheodyne
manual valve model 7125 (Cotati, USA) with 20
"l loop and a recording integrator model C-R6A
Chromatopac (Shimadzu). The mobile phase con-
sisted of acetonitrile–ammonium acetate (25 mM)
(10:90, v/v) adjusted to pH* 5 with concentrated
acetic acid. The flow rate was 0.8 ml/min and
retention times were about 3.5 and 4.4 min for
ceftazidime and pyridine, respectively.
Ceftazidime and pyridine concentrations were
determined by comparing peak areas with stan-
dard curves. Standard curves were determined
daily by using ten standard solutions. Five with
ceftazidime concentrations ranging from 25 to 250
"g/ml and five with pyridine concentrations rang-
ing from 0.1 to 50 "g/ml. The correlation coeffi-
cients for the standard curves were all greater
than 0.999.
Equations for the calibration curves were; for
Ceftazidime, Y (area)=36 119!1998X ("g/ml)+
187 170!15 875; R2=0.9992 (95% confidence
limit) and for pyridine, Y (area)=2249!489X
("g/ml)+2999!142; R2=0.9999 (95% confi-
dence limit).
The intraday coefficients of variation were less
than 1.12% (n=9), and the interday coefficients
of variation were less than 1.8% (n=9), for cef-
tazidime. The intraday coefficients of variation
were less than 3.16% (n=9), and the interday
coefficients of variation were less than 4.37% (n=
9), for pyridine.
The limits of quantitation were 2 ng for both
compounds and the limits of detection were 50
and 20 pg for ceftazidime and pyridine, respec-
tively. The first term was defined as the lowest
level assayed with an R.S.D. of 10% and the
second was based on signal-to-noise ratio of 3:1.
Mean recovery was estimated at 103.6!1.9%
for ceftazidime in the range of 2–250 "g/ml and
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100.5!2.9% for pyridine in the range 0.1 and 50
"g/ml. Homogeneity of S.D. was proved with the
Cochran statistical test.
To establish the stability-indicating nature of
the assay method, ceftazidime was undergone
forced neutral, acidic and basic hydrolysis. Three
water solutions of ceftazidime 100 "g/ml were
made, one was adjusted at pH 1 with concen-
trated hydrochloride acid, the second at pH 12
with concentrated sodium hydroxide, the last one
was used as a standard. Solutions were incubated
at 80 °C for 1 h.
2.5. Statistical analysis
Linear regression of pyridine formation versus
time was used. Comparison of different ambula-
tory pumps was based on median value of pyri-
dine concentration. General Linear
Model-analysis of variance (ANOVA), Student’s
t-paired test and One way-ANOM analysis led
statistical intra- and inter-device comparison
study. A P-value "0.05 was considered statisti-
cally significant.
3. Results and discussion
3.1. Chromatography
In the accelerated degradation studies, the cef-
tazidime and pyridine peaks were well resolved
from any observed degradation products. The
other degradation product peak did not interfere
with drug quantification. The purity of chromato-
graphic peaks, ceftazidime and pyridine, was
confirmed by liquid chromatograph HP 1100 Se-
ries (Agilent Technologies, Palo Alto, USA)
equipped with diode array detector. Both peaks
showed a purity index superior at the limit chosen
by the software HPchem®. No other compounds
were co-eluted with two peaks of interest.
3.2. Stability study
Estimation of ceftazidime stability by monitor-
ing pyridine was a choice based on several studies
previously reported. Indeed, ceftazidime showed a
concentration-dependent first-order rate constants
for its hydrolysis in advanced works on chemical
stability of the molecule [7–9]. Besides, the pyri-
dine concentration according to time was addi-
tional in that of ceftazidime like shown by other
studies [16,20–22]. According to these different
results, it would seem so that monitoring of pyri-
dine can be a sure label of ceftazidime stability in
portable infusion device or all containers. The
only critical parameter was the behaviour of pyri-
dine with wall of filled containers. The sorption
phenomenon was weak and will be developed in
other work [23].
Drug stability was considered clinically accept-
able if 90% or more of the original concentration
remained. Here, the stability was also estimated
by pyridine concentration. At the initial time,
concentration of pyridine should not be higher
than 0.016% (w/v) in infusion solutions, corre-
sponding to 0.4% w/w allowed by USP [17] in dry
mixture. The stability was calculated when per-
centage of pyridine was equal to 0.052% weight
(g) by volume unity, or 520 "g/ml in infusion,
corresponding to a 10% reduction in the initial
ceftazidime concentration, in the same solutions.
This method was based on two previous studies
[15,16].
The stability results are summarised in Table 1
and appearance of pyridine versus time was noted
in Table 2.
Behaviour of different lots of device was statis-
tically identical for the same type of solution.
Nevertheless, formation of pyridine was statisti-
cally different in 0.9% sodium chloride solution
and 5% dextrose solution. These calculations were
shown by a multivariate ANOVA called Linear
General Model at 12 h. This value was defined by
the pyridine concentration median. So, the stabil-
ity of Fortum®, in each device, was in accordance
with the infusion solution kind, as described pre-
viously [12]. The ceftazidime was more stable in
sodium chloride solution, excepted for OutBound
where it was statistically identical after 12 h at
37 °C.
A inter-batch variability was exhibited in Bax-
ter Infusor and Fresenius Ultraflow with 0.9%
NaCl solution. Braun Easypump and Zambon
Outbound did not show variability. For Braun,
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availability of a single lot explained this fact. The
Zambon’s supplies exhibited, in 0.9% NaCl as
well as 5% Dextrose, weak S.D. values. The cef-
tazidime stability was lot-independent for this
device, in NaCl and dextrose injections.
In 5% dextrose, a inter-lot variability was found
in Fresenius OutBound. Therefore, the statistical
study, by one-way ANOM analysis, showed that
the stability in D5% was significantly greater than
other ones.
In 0.9% sodium chloride injection, there was
not significant differences of the stability between
manufacturers. Easypump showed the better be-
haviour, but the conclusion was careful. Indeed,
only one lot was studied.
Attention could be given on infused pyridine
quantity in virtual patient after 24 h therapy,
when the 40 mg/ml concentration was used. A
previous study reported that quantity of pyridine
was equal at 50 mg in 100-ml pump after 14 days
of storage at 4 °C [19], with an initial ceftazidime
concentration of 60 mg/ml. All premature conclu-
sion should be avoided for the numbers shown in
Tables 1 and 2. The reason was the following,
study was led in ceftazidime concentration. So,
the device possessing the greater volume will in-
fuse the greater mass of pyridine. In accordance
with that all device had an identical degradation
kinetic. Nevertheless, these pyridine levels, by its
toxicity, were certainly clinical sound.
4. Conclusion
The method described in this study allows to
quantify ceftazidime and pyridine simultaneously
in single run. It was fast, simple and sensitive.
Although estimation of a compound stability by
monitoring this degradation compound was sel-
dom, this method appeared, in the case of For-
tum, like a good alternative, as reported by
several authors.
Fresenius device showed an injection indepen-
dent ceftazidime stability and exhibited weaker
pyridine concentration in D5% after 12 h of infu-
sion. The four systems did not have statistically
Table 1
Appearance of pyridine in "g/ml in four portable infusion devices filled with 40 mg/ml ceftazidime injection




20 h16 h12 h8 h 24 h4 h
567.6!34.9Baxter 717.0!4.80.9% NaCl 883.5!17.8*1.8!0.7 119.4!6.0 268.8!14.3 418.2!9.9
412.7!58.6 626.1!6.5 839.6!80.9 1052.9!50.9 1266.4!69.7Infusor® 18.6!2.9Dextrose 5% 199.3!13.9
256.7!23.9 409.3!12.4 561.8!46.1 714.4!235.2 866.9!2.8Braun 16.1!1.70.9% NaCl 104.1!4.8
988.3!5.2835.7!12.1683.2!10.5530.6!10.4378.0!1.7Easypump® 225.5!2.586.7!1.0Dextrose 5%
539.8!89.10.9% NaCl 726.6!23.7 913.5!17.2 1100.4!162.99.2!1.4 166.0!12.9 352.9!26.4Fresenius
Dextrose 5% 90.7!0.7 255.0!2.1 390.5!5.7Ultraflow® 525.9!14.6 661.4!21.6 796.8!7.3 932.3!6.2
133.1!5.88.6!3.3 914.9!4.7758.5!0.85602.2!1.9445.8!5.30.9% NaCl 289.5!2.4Zambon
Outbound® 19.4!5.7 279.3!3.5 512.4!13.0 745.6!14.9 978.7!11.4 1211.9!146.4Dextrose 5% 1445.1!71.4
Values are mean!S.D. of triplicate determination for three samples, excepted two samples for *, because one Baxter Infusor has
infused solution in time less than 24 h.
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significant differences in NaCl. Zambon did not
show intra-batch variability, but apparition of
pyridine was more marked than other ones in
D5%, on 12 h.
The infusion solution should be chosen as NaCl
for ceftazidime. Also, the selection of infusion
device for use in ambulatory care is function of
flow-rate accuracy, the cost of disposable supplies,
the type of therapy administered and the comfort
of patients.
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